首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Living-related liver transplantation for primary biliary cirrhosis.
【24h】

Living-related liver transplantation for primary biliary cirrhosis.

机译:与生活相关的肝移植治疗原发性胆汁性肝硬化。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The prognosis of patients with primary biliary cirrhosis has improved since the introduction of transplantation. However, there has been limited experience with living-related liver transplantation for primary biliary cirrhosis. PATIENTS AND METHODS: Between January 1996 and October 2000, 105 patients underwent living-related liver transplantation at the University of Tokyo Hospital. Eighteen of these patients with primary biliary cirrhosis were the subjects of this study. The risk scores in the conventional and updated Mayo models ranged from 5.9 to 11.6 and 6.9 to 13.7, respectively. RESULTS: The graft weight ranged from 330 to 533 g, corresponding to 33 to 55% of the recipient's standard liver volume. Two patients died of pneumonia, 1 died due to sepsis, and the remaining 15 patients survived. The risk scores for the conventional and updated Mayo models correlated well with the duration of hospitalization (P=0.01, R=0.67 for both). The scores of the dead patients by the two models were more than 10 and 12, respectively. The postoperative courses of all of the donors were uneventful. CONCLUSIONS: The risk score in the Mayo model adequately reflected the outcome of the patients. To achieve the best possible outcome, further therapeutic tactics are necessary for patients with conventional or updated Mayo risk scores of more than 10 or 12, respectively.
机译:背景:自移植手术以来,原发性胆汁性肝硬化患者的预后已有改善。然而,与生活相关的肝移植治疗原发性胆汁性肝硬化的经验有限。患者与方法:1996年1月至2000年10月,在东京大学医院对105例患者进行了与生活有关的肝移植。这些原发性胆汁性肝硬化患者中有18位是本研究的对象。常规和更新的Mayo模型中的风险评分分别为5.9至11.6和6.9至13.7。结果:移植物重量为330至533 g,相当于接受者标准肝脏体积的33至55%。 2例患者死于肺炎,1例因败血症死亡,其余15例患者幸存。常规和更新的Mayo模型的风险评分与住院时间密切相关(两者均为P = 0.01,R = 0.67)。两种模型对死亡患者的评分分别超过10和12。所有捐助者的术后病程都很顺利。结论:Mayo模型中的风险评分充分反映了患者的结局。为了获得最佳可能结果,常规或更新的Mayo风险评分分别超过10或12的患者必须采取进一步的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号